{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:41:29Z","timestamp":1762868489860},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T00:00:00Z","timestamp":1618704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The purpose of this retrospective study was to investigate survival outcomes and irradiated tumor control (local control [LC]) and locoregional control (LRC) after stereotactic body radiotherapy (SBRT) for T1 or recurrent T1 (rT1) kidney cancer. Twenty-nine nonconsecutive patients with 30 tumors were included. SBRT doses of 70\u00a0Gy, 60\u00a0Gy or 50\u00a0Gy in 10 fractions were prescribed with a linear accelerator using daily image guidance. The Kaplan\u2013Meier method was used to estimate time-to-event outcomes, and the log-rank test was used to compare survival curves between groups divided by each possible factor. The median follow-up periods for all patients and survivors were 57\u00a0months and 69.6\u00a0months, respectively. The five-year LC rate, LRC rate, progression-free survival (PFS) rate, disease-specific survival (DSS) rate and overall survival (OS) rate were 94%, 88%, 50%, 96% and 68%, respectively. No significant factor was related to OS and PFS. Three of 24 non-hemodialysis (HD) patients had new-onset-HD because of the progression of underlying kidney disease. Grade 3 or higher toxicities from SBRT did not occur. In conclusion, SBRT for kidney cancer provided a high rate of LC, LRC and DSS with minimal toxicities, but patient selection and indication for SBRT should be done carefully considering the relatively low OS rate.<\/jats:p>","DOI":"10.1093\/jrr\/rrab031","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T20:12:11Z","timestamp":1616443931000},"page":"533-539","source":"Crossref","is-referenced-by-count":17,"title":["Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute"],"prefix":"10.1093","volume":"62","author":[{"given":"Takaya","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihide","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Umezawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Kadoya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yojiro","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousei","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Jingu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"2021070802533981800_ref1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/jnci\/djj362","article-title":"Rising incidence of small renal masses: a need to reassess treatment effect","volume":"98","author":"Hollingsworth","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2021070802533981800_ref2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0090-4295(00)00534-3","article-title":"Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982\u20131997)","volume":"56","author":"Luciani","year":"2000","journal-title":"Urology"},{"key":"2021070802533981800_ref3","volume-title":"Clinical Practice Guidelines in Oncology. Kidney Cancer, Version 1","author":"National Comprehensive Cancer Network","year":"2021"},{"key":"2021070802533981800_ref4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021070802533981800_ref5","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2014.55.9567","article-title":"Radical irradiation of extracranial oligometastases","volume":"32","author":"Salama","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021070802533981800_ref6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"2021070802533981800_ref7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jvir.2019.11.009","article-title":"Stereotactic body radiotherapy for stage I renal cell carcinoma: national treatment trends and outcomes compared to partial nephrectomy and thermal ablation","volume":"31","author":"Uhlig","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"2021070802533981800_ref8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5489\/cuaj.2900","article-title":"Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: current evidence and future directions","volume":"9","author":"Swaminath","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"2021070802533981800_ref9","volume-title":"Phase I\/II study of stereotactic radiotherapy for renal cell cancer"},{"key":"2021070802533981800_ref10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13014-016-0651-5","article-title":"Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma","volume":"11","author":"Yamamoto","year":"2016","journal-title":"Radiat Oncol"},{"key":"2021070802533981800_ref11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2021070802533981800_ref12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2018.03.011","article-title":"Active surveillance for localized renal masses: tumor growth, delayed intervention rates, and &gt;5-yr clinical outcomes","volume":"74","author":"McIntosh","year":"2018","journal-title":"Eur Urol"},{"key":"2021070802533981800_ref13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.eururo.2011.03.030","article-title":"Active surveillance of small renal masses: progression patterns of early stage kidney cancer","volume":"60","author":"Jewett","year":"2011","journal-title":"Eur Urol"},{"key":"2021070802533981800_ref14","doi-asserted-by":"crossref","first-page":"E737","DOI":"10.1111\/j.1464-410X.2012.11550.x","article-title":"A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma","volume":"110","author":"Siva","year":"2012","journal-title":"BJU Int"},{"key":"2021070802533981800_ref15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"2021070802533981800_ref16","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12885-018-4916-2","article-title":"TROG 15.03 phase II clinical trial of focal ablative stereotactic radiosurgery for cancers of the kidney \u2013 FASTRACK II","volume":"18","author":"Siva","year":"2018","journal-title":"BMC Cancer"},{"key":"2021070802533981800_ref17","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818822329","article-title":"Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy","volume":"18","author":"Funayama","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"2021070802533981800_ref18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"2021070802533981800_ref19","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1080\/02841860802123196","article-title":"Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney","volume":"47","author":"Svedman","year":"2008","journal-title":"Acta Oncol"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/62\/3\/533\/37907429\/rrab031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/62\/3\/533\/37907429\/rrab031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T07:02:39Z","timestamp":1625727759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/62\/3\/533\/6232581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,4,19]]},"published-print":{"date-parts":[[2021,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrab031","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5]]},"published":{"date-parts":[[2021,4,19]]}}}